The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The approval is backed by data showing deep, durable responses and manageable tolerability
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
